Clinical Trials Directory

Trials / Completed

CompletedNCT00646581

Effect of Single Dose Intranasal Insulin On Cognitive Function

Effect of Single Dose Intranasal Insulin on Cognitive Function in Patients With Schizophrenia

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
30 (actual)
Sponsor
University of Massachusetts, Worcester · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders. Insulin is not being used to treat diabetes in this study. The investigators propose a single dose, double-blinded, placebo-controlled trial of intranasal insulin in 40 subjects with schizophrenia or schizoaffective disorder to examine insulin's effect on cognition. The specific aims include: 1. Examine the effects of single doses of 40 IU intranasal insulin compared to placebo on cognitive functioning, including attention and memory. 2. Examine whether single dose of intranasal insulin administration will raise serum insulin level and decrease plasma glucose level Insulin will be delivered through an air spray pump into your nose. The investigators will be comparing one dose of insulin (40 International Units) with placebo, an inactive liquid.

Detailed description

Insulin signaling in the brain is associated with improved cognitive function in both animal and human studies. Intranasal administration of insulin, which is non-invasive and minimizes the risk of hypoglycemia, may represent a new intervention approach with the potential to improve cognition and real life functioning in this patient with schizophrenia.

Conditions

Interventions

TypeNameDescription
DRUGPlaceboPlacebo
DRUGInsulin (Humulin)40 IU Intranasal Insulin will be administered once

Timeline

Start date
2006-10-01
Primary completion
2010-01-01
Completion
2010-01-01
First posted
2008-03-28
Last updated
2013-02-15
Results posted
2013-01-29

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00646581. Inclusion in this directory is not an endorsement.